Probatebeta
Target

CD38

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1

As of the edition of 20 October 2026, CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, UniProt P28907) has 15 drugs tested at it and 16 companies on the list, 6 on route A and 2 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P28907
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
56
Disease areas
Cancer; Immune system; Blood and lymph; Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue
Registered trials of its drugs
465

Drugs at this target

StatusCount
Marketed2
Active5
Stopped6
Status not established2
Total15
DrugStatusFurthest phaseUS protection
DaratumumabMarketedPhase 4Ends 2028
IsatuximabMarketedPhase 4Ends 2032
FelzartamabActivePhase 3none listed
MezagitamabActivePhase 3none listed
Modakafusp alfaStoppedPhase 2none listed
STI-6129ActivePhase 2none listed
CID-103ActivePhase 2none listed
MT-0169StoppedPhase 1none listed
AMG 424StoppedPhase 1none listed
IGM-2644StoppedPhase 1none listed
ISB 2001ActivePhase 1none listed
SAR442085Status not establishedPhase 1none listed

12 of 15 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A6
Route B2
Engaged6
Undetermined2
Total on the list16
Three companies on route A or B, with the route only
CompanyRoute
SanofiRoute B
Johnson & JohnsonRoute B
TJ BiopharmaRoute A

The other 13 companies at CD38

In the product

16 companies in all; 13 are not named here, and no score is.

See the 16 companies at CD38, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at CD38

Other targets in cancer